



Cite this: *Chem. Sci.*, 2019, 10, 9853

All publication charges for this article have been paid for by the Royal Society of Chemistry

Received 10th July 2019
Accepted 31st August 2019

DOI: 10.1039/c9sc03406d

rsc.li/chemical-science

Enantioselective synthesis of quaternary 3,4-dihydroisoquinolinones *via* Heck carbonylation reactions: development and application to the synthesis of Minalrestat analogues†

Cang Cheng, Bin Wan, Bo Zhou, Yichao Gu and Yanghui Zhang *

Minalrestat and its analogues represent structurally novel aldose reductase inhibitors, and the asymmetric synthesis of such pharmaceutically privileged molecules has not been reported yet. We have developed a palladium-catalyzed enantioselective intramolecular carbonylative Heck reaction by using formate esters as the source of CO, which represents the first enantioselective synthesis of quaternary 3,4-dihydroisoquinolines. The reaction provides a facile and efficient method for the synthesis of enantiopure nitrogen-containing heterocyclic compounds bearing an all-carbon quaternary stereocenter. The reaction has been successfully applied to the first asymmetric synthesis of Minalrestat analogues.

Introduction

Diabetes mellitus is a major health concern and affects millions of people worldwide.¹ Aldose reductase inhibitors (ARIs) are attractive therapeutic targets for designing drugs to prevent or slow the progression of diabetic complications.² Although various ARIs have been discovered, almost all of them have been withdrawn due to adverse side effects or low efficacy.³ Minalrestat is an important ARI that shows appreciable activity and safety profiles and is a promising drug candidate.⁴ Minalrestat is a 3,4-dihydroisoquinolinone derivative bearing a spiro-succinimide moiety at the 4-position (Fig. 1). Actually, the isoquinolinone backbone in Minalrestat represents a structurally novel framework for designing potent ARIs, and a range of derivatives derived from the backbone exhibit intrinsic activity and good oral potency.⁴ Notably, these bioactive isoquinolinone derivatives usually contain a quaternary carbon stereocenter, and the stereocenter plays crucial roles in the bioactivities and oral potency. Unfortunately, the stereocenters tend to racemize *via* enolization.^{4a} The asymmetric synthesis of this isoquinolinone skeleton is not available,⁵ and the enantiopure compounds were obtained by the resolution of racemates.^{4a} Therefore, it is a formidable task to develop enantioselective reactions for the construction of such six-membered isoquinolinones containing an all-carbon quaternary stereocenter,

which would allow us to not only obtain enantiopure compounds for drug discovery but also modify the structures to prevent racemization.

3,4-Dihydroisoquinolinone skeletons are widely found in natural products and are pivotal structural motifs in drug molecules,⁶ and many of the bioactive 3,4-dihydroisoquinolinone derivatives contain an all-carbon quaternary stereocenter at the 4-position⁷ (Fig. 1). As such, asymmetric reactions for the construction of such isoquinolinone skeletons would find wide applications in organic synthesis. Although




Fig. 1 Bioactive 3,4-dihydroisoquinolinone derivatives containing all-carbon quaternary stereocenters at the 4-position.

School of Chemical Science and Engineering, Shanghai Key Laboratory of Chemical Assessment and Sustainability, Tongji University, 1239 Siping Road, Shanghai 200092, China. E-mail: zhangyanghui@tongji.edu.cn

† Electronic supplementary information (ESI) available: Full experimental details and characterisation. CCDC 1921698. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c9sc03406d



编号: 2020TJJS150522

证 明

经检索 Science Citation Index Expanded (SCI-EXPANDED) 数据库、Journal Citation Reports (JCR) 数据库, 同济大学化学科学与工程学院程沧的如下 1 篇论文被 SCI 收录, 并附最新 (2018) 期刊影响因子。

详细如下:

第 1 条, 共 1 条

标题: Enantioselective synthesis of quaternary 3,4-dihydroisoquinolinones via Heck carbonylation reactions: development and application to the synthesis of Minalrestat analogues

作者: Cheng, C (Cheng, Cang); Wan, B (Wan, Bin); Zhou, B (Zhou, Bo); Gu, YC (Gu, Yichao); Zhang, YH (Zhang, Yanghui)

来源出版物: CHEMICAL SCIENCE 卷: 10 期: 42 页: 9853-9858 DOI: 10.1039/c9sc03406d 出版年: NOV 14 2019

Web of Science 核心合集中的 "被引频次": 3

被引频次合计: 3

入藏号: WOS:000493521200023

文献类型: Article

地址: [Cheng, Cang; Wan, Bin; Zhou, Bo; Gu, Yichao; Zhang, Yanghui] Tongji Univ, Shanghai Key Lab Chem Assessment & Sustainabil, Sch Chem Sci & Engn, 1239 Siping Rd, Shanghai 200092, Peoples R China.

通讯作者地址: Zhang, YH (通讯作者), Tongji Univ, Shanghai Key Lab Chem Assessment & Sustainabil, Sch Chem Sci & Engn, 1239 Siping Rd, Shanghai 200092, Peoples R China.

电子邮件地址: zhangyanghui@tongji.edu.cn

ISSN: 2041-6520

eISSN: 2041-6539

期刊影响因子 (2018 年): 9.556

期刊 JCR 分区:

JCR® 类别	类别中的排序	JCR 分区
CHEMISTRY, MULTIDISCIPLINARY	19/172	Q1

数据来自第 2018 版 Journal Citation Reports

特此证明!



同济大学科技情报所

检索人: 郑晓云

2020 年 06 月 24 日

Synthesis of 3,4-Fused Tricyclic Indoles through Cascade Carbopalladation and C–H Amination: Development and Total Synthesis of Rucaparib

Cang Cheng, Xiang Zuo, Dongdong Tu, Bin Wan, and Yanghui Zhang*

Cite This: <https://dx.doi.org/10.1021/acs.orglett.0c01513>

Read Online


ACCESS |

Metrics & More

Article Recommendations

Supporting Information

ABSTRACT: 3,4-Fused tricyclic indole scaffolds are ubiquitous in bioactive natural products and pharmaceuticals. A new protocol for the synthesis of 3,4-fused tricyclic indoles has been developed through cascade carbopalladation and C–H amination with *N,N*-di-*tert*-butyldiaziridinone. The protocol allows access to a range of 3,4-fused tricyclic indoles, including those containing various linkers and fused with medium-sized rings. Rucaparib can be synthesized via this reaction, providing an advantageous synthetic method for the FDA-approved cancer medicine.



3,4-Fused tricyclic indoles are essential core structures of many bioactive natural products and pharmaceuticals and are attractive synthetic targets in the fields of medicinal chemistry and organic synthesis (Figure 1).¹ The synthesis of these




Figure 1. Selected examples of 3,4-fused tricyclic indoles.

complex indole molecules is challenging and has been the subject of numerous synthetic studies.² Traditionally, 3,4-fused tricyclic indoles can be synthesized by the intramolecular cyclization of 4-substituted or 3,4-disubstituted indoles. However, the functionalization of the four-positions of indoles is challenging and usually requires multistep synthesis. Recently, the construction of 3,4-fused tricyclic indoles via indole ring formation has gained considerable interest. Compared with the traditional methods, this innovative approach avoids the laborious synthesis of four-substituted indole precursors and has great advantages. An elegant example is the method based on an intramolecular Fischer indole synthesis, which was developed by Cho and coworkers.³ In 2013, the groups of Boger and Jia reported the synthesis of

3,4-fused tricyclic indoles using alkyne-tethered *ortho*-iodoanilines via palladium-catalyzed intramolecular Larock indole synthesis.⁴ Replacing the alkyne moiety with an allene group can also give 3,4-fused tricyclic indoles.⁵ The intramolecular Larock indole syntheses require the presynthesis of multi-substituted haloanilines as starting materials. Notably, an innovative method through C–H alkenylation using anilines tethered to an alkyne at the meta position has been independently developed by the groups of Jia, Xu and Liu, Zhou and Li, and Nemoto.⁶ However, to activate more hindered C–H bonds, the reactions are restricted to indoles bearing an alkoxy group.^{2a} The group of Miura and Murakami disclosed an elegant dearomatizing annulation reaction from 1,2,3-triazole-tethered arenes.⁷ However, this method requires an additional oxidation reaction to form indole products and the presynthesis of 1,2,3-triazole-containing substrates. In all of these reactions, 3,4-fused tricyclic indoles are directly formed from the intramolecular cyclization of the substrates, and all of the substrates preinstalled with a nitrogen-containing group are used.⁸ Considerable efforts should still be devoted to developing efficient and general methods for the synthesis of 3,4-fused tricyclic indoles.

Over the past several decades, transition-metal-catalyzed C–H functionalization underwent explosive growth.⁹ C–H

Received: May 2, 2020

网页检索证明

https://pubs.acs.org/doi/10.1021/acs.orglett.0c01513

ACS Publications CAS

Search text, DOI, authors, etc.

My Activity Publications

c&en WEBINARS
Analysis of Viral Proteins, Monoclonal Antibodies and their Interactions with Light Scattering
REGISTER NOW

COVID-19 Remote Access Support: Learn More about expanded access to ACS Publications research.

RETURN TO ARTICLES ASAP < PREVIOUS LETTER NEXT >

Synthesis of 3,4-Fused Tricyclic Indoles through Cascade Carbopalladation and C–H Amination: Development and Total Synthesis of Rucaparib

Cang Cheng, Xiang Zuo, Dongdong Tu, Bin Wan, and Yanghui Zhang*

Cite this: *Org. Lett.* 2020, XXXX, XXX, XXX-XXX
Article Views: 533 | Altmetric: - | Citations: -
Publication Date: June 17, 2020
https://doi.org/10.1021/acs.orglett.0c01513
Copyright © 2020 American Chemical Society
RIGHTS & PERMISSIONS ✓ Subscribed

Share Add to Export
RIS

Organic Letters

PDF (1 MB) Supporting Info (1) » SUBJECTS: Indoles, Hydrocarbons, Organic synthesis, Organic reactions, Cyclization

Abstract

3,4-Fused tricyclic indole scaffolds are ubiquitous in bioactive natural products and pharmaceuticals. A new protocol for the synthesis of 3,4-fused tricyclic indoles has been developed through cascade carbopalladation and C–H amination with *N,N*-di-*tert*-butyldiaziridinone. The protocol allows access to a range of 3,4-fused tricyclic indoles, including those containing various linkers and fused with medium-sized rings. Rucaparib can be synthesized via this reaction, providing an advantageous synthetic method for the FDA-approved cancer medicine.

Various ring sizes
Various linkers
37 examples
up to 99% yield

Practical synthesis of Rucaparib
FDA-approved cancer medicine.

我为主公谢江山

我的视频 头条推荐 热点资讯